AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows.

In the Claims

- 1. (Currently amended) A <u>transgenic mouse</u> non-human animal model of oligodendrocyte developmental disorders wherein the <u>transgenic mouse</u> non-human animal comprises a <u>deficiency disruption</u> in chromosomal DAP12 (DNAX Activation Protein 12) gene function, and <u>wherein the transgenic mouse</u> shows <u>hypomyelinosis of the thalamus</u> an <u>oligodendrocyte</u> <u>developmental disorder</u>.
- 2. (Currently amended) The <u>transgenic mouse</u> non-human animal model of claim 1, wherein the <u>disruption in DAP12 includes the promoter region and exons 1, 2 and 3 non-human animal is a mouse</u>.
- 3. (Currently amended) The <u>transgenic mouse</u> non-human animal model of claim 1, wherein the oligodendrocyte developmental disorder is a myelinogenesis developmental disorder <u>or a neuropsychiatric disorder</u>.
- 4. (Currently amended) The <u>transgenic mouse</u> non-human animal model of claim 4 3, wherein the oligodendrocyte developmental disorder is a neuropsychiatric disorder is selected from the group consisting of Nasu-Hakola disease, dementia, schizophrenia, schizotypal personality disorders, obsessive-compulsive disorders, Huntington's disease or Tourette's syndrome.
- 5. (Currently amended) The <u>transgenic mouse</u> non-human animal model of claim 3, wherein the <u>myelinogenesis developmental disorder is a</u> neuropsychiatric disorder <u>is selected</u> from the group consisting of Nasu-Hakola disease, <u>or</u> dementia, schizophrenia, schizotypal personality disorders, obsessive compulsive disorders, Huntington's disease or Tourette's syndrome.
- 6-18. (Canceled)
- 19. (New) The transgenic mouse model of claim 1, wherein the expression of myelin basic protein in the brain is weak in regions where DAP12 is strongly expressed in wild-type mice.
- 20. (New) The transgenic mouse model of claim 1, wherein the transgenic mouse exhibits an impairment in sensorimotor gating as compared to wild-type mice.

2

00343553